BiomX (NYSEMKT:PHGE) Given Buy Rating at HC Wainwright

BiomX (NYSEMKT:PHGE)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $21.00 price objective on the stock. HC Wainwright also issued estimates for BiomX’s Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.08) EPS and FY2028 earnings at ($1.84) EPS.

BiomX Price Performance

The firm has a market cap of $13.89 million, a P/E ratio of -0.76 and a beta of 1.38. BiomX has a 1 year low of $0.48 and a 1 year high of $4.99. The stock’s fifty day moving average is $0.71 and its 200-day moving average is $0.75. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84.

Institutional Investors Weigh In On BiomX

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PHGE. JPMorgan Chase & Co. purchased a new position in shares of BiomX in the fourth quarter valued at approximately $314,000. Allostery Investments LP acquired a new position in shares of BiomX in the fourth quarter worth $470,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of BiomX in the fourth quarter worth $632,000. Hedge funds and other institutional investors own 40.57% of the company’s stock.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.